Life Sciences Vacancy Rates Hit Record High, Deflating Rents
ByAinvest
Saturday, Sep 13, 2025 8:20 am ET1min read
CWK--
The U.S. life sciences vacancy rate rose by 70 basis points quarter-over-quarter and 520 basis points from a year ago. The construction pipeline, which accounts for 3% of inventory, indicates a shift from speculative to build-to-suit construction, with 63% of the space under construction already pre-leased [1].
Asking rents for lab and Current Good Manufacturing Practice (cGMP) space grew by an average of 0.7% from the end of 2024 across 16 major markets examined by Cushman & Wakefield. However, rents in some key markets, such as Boston (-1.3%) and San Francisco Bay Area (-2.1%), experienced declines. Vacant sublease space increased by 10 basis points in the quarter to 4.0%, contributing to lower average asking rents [1].
The slowdown in construction, currently at its lowest level since 2019 at just under 8 million square feet, is expected to help the market absorb the vacant space delivered over the past two years. This should help normalize high vacancy rates in some markets over the longer term [1].
Although asking rents are expected to further soften this year, the trend is not expected to persist long-term. The softening should ebb as uncertainty subsides, according to the report. Even with the softening, rents in the sector still command a premium over office rents, with life sciences rents being 31% higher than office rents in the 12 U.S. markets tracked by Cushman & Wakefield. This premium is even more pronounced in Boston (75%) and San Diego (70%) [1].
Life sciences market vacancy rates in the US reached a new high of 23.9% in Q2, leading to further softening in asking rents and concessions. The construction pipeline accounts for 3% of inventory, with 63% of the space under construction already pre-leased, signaling a shift from speculative to build-to-suit construction. Asking rents for lab and cGMP space grew 0.7% from the end of 2024, while rents in some key markets, such as Boston and San Francisco, experienced declines.
Life sciences market vacancy rates in the US reached a new high of 23.9% in the second quarter of 2025, according to a recent report by Cushman & Wakefield. This increase led to further softening in asking rents and concessions, as the market continues to grapple with soft demand and a wave of vacant new construction completions [1].The U.S. life sciences vacancy rate rose by 70 basis points quarter-over-quarter and 520 basis points from a year ago. The construction pipeline, which accounts for 3% of inventory, indicates a shift from speculative to build-to-suit construction, with 63% of the space under construction already pre-leased [1].
Asking rents for lab and Current Good Manufacturing Practice (cGMP) space grew by an average of 0.7% from the end of 2024 across 16 major markets examined by Cushman & Wakefield. However, rents in some key markets, such as Boston (-1.3%) and San Francisco Bay Area (-2.1%), experienced declines. Vacant sublease space increased by 10 basis points in the quarter to 4.0%, contributing to lower average asking rents [1].
The slowdown in construction, currently at its lowest level since 2019 at just under 8 million square feet, is expected to help the market absorb the vacant space delivered over the past two years. This should help normalize high vacancy rates in some markets over the longer term [1].
Although asking rents are expected to further soften this year, the trend is not expected to persist long-term. The softening should ebb as uncertainty subsides, according to the report. Even with the softening, rents in the sector still command a premium over office rents, with life sciences rents being 31% higher than office rents in the 12 U.S. markets tracked by Cushman & Wakefield. This premium is even more pronounced in Boston (75%) and San Diego (70%) [1].
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue

Comments
No comments yet